Profile for European Patent Office Patent: 3191475
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Denmark | CA 2024 00052 | ⤷ Start Trial |
| Lithuania | PA2024541 | ⤷ Start Trial |
| Netherlands | 301307 | ⤷ Start Trial |
| Luxembourg | LUC00372 | ⤷ Start Trial |
| Denmark | CR 2024 00052 | ⤷ Start Trial |
| Germany | 122024000069 | ⤷ Start Trial |
| Austria | 47/2024 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 3191475
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Sep 7, 2035 | Takeda Pharms Usa | FRUZAQLA | fruquintinib |
| ⤷ Start Trial | Sep 7, 2035 | Takeda Pharms Usa | FRUZAQLA | fruquintinib |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
